ArticleCancer cell international2026
An herbal formula, SH003 alleviates colorectal cancer through dual targeting of adaptive and innate checkpoints PD-L1/CD47.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is the third most common cancer. The use of immunotherapy for cancer has become widespread in recent decades and adaptive and innate checkpoints can be simultaneously targeted for enhanced immunotherapy. An herbal formula, SH003 has beneficial effects against multiple cancers. However, the anti-CRC efficacy of SH003 through dual targeting of adaptive and innate checkpoints, PD-L1/CD47 remain to be investigated.
methodsWe used two types of CRC patient-derived organoids (PDOs) and two types of CRC cell lines, and analyzed PD-L1 and CD47 expression levels with quantitative real-time PCR, Western blot, flow cytometry assays, and immunofluorescence staining. The cytotoxicity, proliferation, and apoptosis analysis were applied to clarify the regulatory effects on CRC growth. T cell immunity was analyzed through a co-culture system of CRC cell lines and T cells, as well as in in vivo CRC model.
resultsSH003 reduced the growth of CRC PDOs, leading to morphological changes and decreases in ATP and Ki67 levels. SH003 inhibited the mRNA and protein expression of both PD-L1 and CD47 though the regulation of c-Myc in CRC PDOs. In addition, SH003 suppressed VEGF, TNF-α, and IL-1β in CRC PDOs. This effect was validated in experiments of CRC cell lines, revealing that SH003 suppressed both PD-L1 and CD47 expression increased by IFN-γ stimulation via the regulation of c-Myc and reduced CRC progression. SH003 also enhanced the T cell-mediated killing of CRC cells with increased IL-2 production. In an in vivo CRC model, SH003 inhibited tumor growth while reducing both PD-L1, CD47, and c-Myc expression and increasing CD8
conclusionsOur investigation demonstrated that SH003 served as a novel CRC immunotherapy by the dual targeting of adaptive and innate checkpoints, PD-L1/CD47 via the regulation of c-Myc signaling, highlighting that SH003 may be an effective herbal candidate drug for the treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.